Related Experiment Videos
Botulinum toxin type B for cervical dystonia.
J Costa1, C Espírito-Santo, A Borges
1Instituto de Farmacologia e Terapêutica Geral, Faculdade de Medicina Lisboa, Av. Prof. Egas Moniz, Lisboa, Portugal, 1649-028. movementdisord@mail.telepac.pt
The Cochrane Database of Systematic Reviews
|January 28, 2005
Summary
Botulinum toxin type B (BtB) effectively treats cervical dystonia, offering significant symptom improvement. While adverse events like dysphagia occurred, BtB provides a valuable option, especially for patients resistant to Botulinum toxin type A (BtA).
Area of Science:
- Neurology
- Pharmacology
- Medical Research
Background:
- Cervical dystonia, a common focal dystonia, causes involuntary head posturing and neck pain.
- Botulinum toxin type A (BtA) is a first-line therapy, but resistance can develop.
- Botulinum toxin type B (BtB) is investigated as an alternative treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of Botulinum toxin type B (BtB) for cervical dystonia treatment.
- To compare BtB's effectiveness, particularly in patients resistant to Botulinum toxin type A (BtA).
Main Methods:
- Systematic review of randomized, placebo-controlled trials.
- Searched multiple databases (Cochrane, MEDLINE, EMBASE) and handsearched journals.
- Data extraction and validity assessment by two independent reviewers.
Main Results:
- Meta-analysis of three trials (308 participants) showed significant improvement in TWSTRS scores at 4 weeks.
- Subjective assessments of improvement and pain reduction were also noted.
- Adverse events, including dysphagia and dry mouth, were more frequent with BtB; duration of effect was approximately 16 weeks.
Conclusions:
- A single BtB injection is effective and safe for cervical dystonia.
- Long-term studies suggest sustained efficacy with repeat injections.
- Further research is needed on optimal intervals, guidance techniques, quality of life, and comparative indications.